Being overexpressed in a variety of hematologic malignancies and solid tumors, WT1 has been considered as a molecular target of cancer immunotherapy in several solid tumors and as a tool for monitoring minimal residual disease in leukemic patients (Rushing et al., 2010). Here, WT1 is linked to cancer.